QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

被引：0

作者：

Peyrin-Biroulet, L. ^{[1
]}

Rubin, D. ^{[2
]}

Lichtenstein, G. ^{[3
]}

Shipitofsky, N. ^{[4
]}

Huang, K. H. ^{[4
]}

Germinaro, M. ^{[4
]}

Wilson, R. ^{[5
]}

Zhang, H. ^{[5
]}

DuVall, G. A. ^{[6
]}

Cao, Q. ^{[7
]}

Allegretti, J. ^{[8
]}

Feagan, B. ^{[9
]}

Hisamatsu, T. ^{[10
]}

Panes, J. ^{[11
]}

Dignass, A. ^{[12
]}

Bressler, B. ^{[13
]}

Sands, B. ^{[14
]}

机构：

[1] Nancy Univ Hosp, Gastroenterol, Nancy, France

[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[3] Univ Pennsylvania, Dept Med, Div Gastroenterol, Raymond & Ruth Perelman Sch, Philadelphia, PA USA

[4] Janssen Res Dev LLC, Immunol, Spring House, PA USA

[5] anssen Res Dev LLC, Biostat, Spring House, PA USA

[6] Tyler Res Inst LLC, Gastroenterol, Tyler, TX USA

[7] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China

[8] Brigham & Womens Hosp, Crohns & Colitis Ctr, Gastroenterol Hepatol & Endoscopy, Boston, MA USA

[9] Alimentiv Inc, Gastroenterol, London, ON, Canada

[10] Kyorin Univ, Gastroenterol & Hepatol, Tokyo, Japan

[11] CIBERehd, Gastroenterol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[12] Agaples Markus Hosp, Dept Med, Frankfurt, Germany

[13] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[14] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P493

引用

页码：624 / 625

页数：3

共 50 条

[1] QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
Sands, Bruce E.
Rubin, David T.
Lichtenstein, Gary
Shipitofsky, Nicole
Huang, Kuan-Hsiang
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
DuVall, Aaron
Cao, Qian
Allegretti, Jessica R.
Feagan, Brian G.
Peyrin-Biroulet, Laurent
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Bressler, Brian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S526 - S527
[2] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
Rubin, D.
Sands, B.
Lichtenstein, G.
Baker, T.
Huang, K. H.
Germinaro, M.
Miao, Y.
Zhang, H.
Nancey, S.
Allegretti, J.
Feagan, B.
Hisamatsu, T.
Panes, J.
Dignass, A.
Bressler, B.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723
[3] Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Rubin, David T.
Sands, Bruce E.
Lichtenstein, Gary R.
Baker, Thomas
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Miao, Ye
Zhang, Hongyan
Nancey, Stephane
Allegretti, Jessica R.
Feagan, Brian G.
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S672 - S673
[4] Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Peyrin-Biroulet, Laurent
Allegretti, Jessica R.
Rubin, David T.
Bressler, Brian
Germinaro, Matthew
Huang, Kuan-Hsiang
Shipitofsky, Nicole
Zhang, Hongyan
Wilson, Rebbecca
Han, Chenglong
Feagan, Brian G.
Sandborn, William J.
Panes, Julian
Hisamatsu, Tadakazu
Lichtenstein, Gary R.
Sands, Bruce E.
Dignass, Axel
GASTROENTEROLOGY, 2023, 165 (06) : 1443 - 1457
[5] Guselkumab for moderately to severely active ulcerative colitis
不详
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
[6] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Allegretti, Jessica R.
Peyrin-Biroulet, Laurent
Feagan, Brian G.
Bressler, Brian
Lichtenstein, Gary R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Shipitofsky, Nicole
Jiang, Lingjing
Zhang, Hongyan
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Sands, Bruce E.
Rubin, David T.
GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
[7] GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12
Dignass, Axel
Panes, Julian
Rubin, David T.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Pandya, Dwiti
Han, Chenglong
Miao, Ye
Zhang, Hongyan
Gu, Fang
Rowbotham, David S.
Mihaly, Emese
Bressler, Brian
Lichtenstein, Gary R.
Allegretti, Jessica R.
GASTROENTEROLOGY, 2024, 166 (05) : S848 - S849
[8] Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12
Dignass, A.
Panes, J.
Rubin, D. T.
Huang, K. H. G.
Germinaro, M.
Pandya, D.
Han, C.
Miao, Y.
Zhang, H.
Gu, F.
Rowbotham, D.
Mihaly, E.
Bressler, B.
Lichtenstein, G. R.
Allegretti, J. R.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I165 - I166
[9] Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
Lichtenstein, Gary R.
Dignass, Axel
Rubin, David T.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Miao, Ye
Zhang, Hongyan
Kierkus, Jaroslaw
Seidler, Ursula
Maemoto, Atsuo
Allegretti, Jessica R.
Bressler, Brian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S624
[10] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
Allegretti, Jessica R.
Rubin, David T.
Bressler, Brian
Huang, Kuan-Hsiang G.
Shipitofsky, Nicole
Germinaro, Matthew
Zhang, Hongyan
Johanns, Jewel
Feagan, Brian
Sandborn, William J.
Sands, Bruce E.
Hisamatsu, Tadakazu
Lichi, Gary R.
Lichtenstein, Gary R.
Panes, Julian
Dignass, Axel
GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964

← 1 2 3 4 5 →